Glaxo Sotrovimab is a monoclonal antibody treatment U.S. Food and Drug Administration approved for severe COVID-19 cases. The company developed the intravenous injection during the 2003 SARS coronavirus outbreak. However, it is continuing investigating its usefulness during the current epidemic. Latest news reveals Glaxo Sotrovimab medicine works on Omicron variant. Its commercial name is Xevudy.
Glaxo Sotrovimab Effective against All Mutations in Omicron
Fin24 announced the breaking news on December 7, 2021. This was after Glaxo announced success against the full combination of all 37 mutations. However, in this instance they used a pseudo-synthesized version.
The Scientist professional magazine explains pseudo-viruses are accurate models of the real thing, and in use since the 1960’s. However, they have their ‘teeth drawn’ for safe study in laboratories with lower bio-safety levels.
This observation by a reputable pharmaceutical manufacturer under controlled conditions appears to be a welcome confirmation. Confirmation that Omicron may be less successful at eroding medication and vaccines than our medical specialists first feared.
More Confidence with Glaxo Sotrovimab Medicine
Glaxo Sotrovimab reduced the risk of hospitalization and death in people with mild to moderate COVID-19 by 79% in trials. ‘We are confident Sotrovimab will continue to provide significant benefit for the early treatment of patients,’ a spokesperson says. ‘Patients hoping to avoid the most severe consequences of COVID-19’.
But there is a catch as we understand it. Apparently Glaxo Sotrovimab monoclonal treatment’s ability to neutralize Omicron is three-fold less than earlier trials. But Glaxo believes this effect could reverse with larger doses.
None the less we should welcome this news, especially on behalf of immuno compromised people unable to receive vaccines. Moreover, we should remember that vaccines and drugs are only part of our arsenal. We have great hope many of us will never need their protection, because we take practical precautions to prevent infection.
Breaking News
New Insights into Living with Omicron Variant
Prepare for a Future That Will Be Different
Preview Image: Obtaining Monoclonal Antibodies
